Epi Biologics announced it raised $30 Million in an initial filing from an offering of $50.1 Million
Epi Biologics announced it raised $30 Million in an initial filing from an offering of $50.1 Million
04/28/23, 8:55 PM
Location
san mateoMoney raised
$30 million
Industry
biotechnology
Company Info
Location
1900 alameda de las pulgas
san mateo, california, united states
Additional Info
EpiBiologics is building a next-generation protein degradation platform that targets membrane and extracellular proteins. EpiBiologics was founded in 2022 based on the pioneering work from academic founder Dr. Jim Wells of the University of California San Francisco (UCSF). The Company’s proprietary EpiTAC platform is a modular antibody-based system that enables the precise degradation of disease-driving membrane and extracellular proteins in a tissue-specific manner. Headquartered in San Mateo, EpiBiologics is backed by leading healthcare investors and aims to develop first-in-class and best-in-class targeted therapies across multiple therapeutic areas.